Russia claims 80% tumor reduction with new cancer vaccine

A New Hope in the Fight Against Colorectal Cancer

Russian government officials have recently made a groundbreaking claim in the battle against colorectal cancer, although the details remain limited. Veronika Skvortsova, head of Russia's Federal Medical and Biological Agency (FMBA), announced that the country's cancer vaccine, Enteromix, has demonstrated up to 100% effectiveness in preclinical trials. This development has sparked both excitement and skepticism within the scientific community.

Skvortsova stated that the vaccine is now ready for use and is awaiting official approval from Russian regulators. However, these claims have not been independently verified, raising questions about their validity. According to reports, Enteromix was successful in shrinking colorectal tumors and slowing cancer progression during clinical trials. Russian officials also mentioned "promising progress" in developing vaccines for glioblastoma, an aggressive brain cancer, and specific types of melanoma, including ocular melanoma at advanced stages.

Despite these encouraging results, it remains unclear whether the vaccine was tested on humans. Preclinical trials typically involve animals with anatomies significantly different from humans, which complicates the interpretation of the results. The Enteromix vaccine is built on an mRNA platform, similar to the technology used in many of the world’s most effective Covid-19 vaccines.

The mRNA technology works by delivering genetic instructions to cells, prompting them to create harmless viral components that the immune system can recognize and attack. This approach is not exclusive to viruses; it can be adapted to target cancer cells as well. However, the exact mechanism of the Russian vaccine and its true efficacy are still unknown, as no detailed data has been released.

Before Enteromix can be made available to patients, it must receive approval from the Ministry of Health. Russian officials have claimed that the vaccine reduced tumor size in the colon and slowed disease progression by 60 to 80% in preclinical trials. State media has even described it as 100% effective in some cases.

Dr. David James Pinato, a clinician scientist at Imperial College London, expressed concerns about the quality of the data being released. He emphasized that if these are indeed preclinical results, they are promising but should not yet be considered suitable for clinical use. Several personalized mRNA cancer vaccines are currently in various stages of clinical trials, but none have received FDA approval yet.

The term "preclinical" generally refers to tests conducted in animals and petri dishes, but Russian officials did not clarify this or provide any studies documenting the vaccine's development. It is also unclear whether the vaccine is intended for younger individuals or adults who are more susceptible to the disease.

Rising Incidence of Colorectal Cancer in Younger Adults

Colorectal cancer rates are increasing among people under 50, a trend that has puzzled doctors accustomed to seeing the disease in older adults. Since 2004, incidence rates have risen steadily by 1.6% annually in adults aged 20 to 39. The increase is even more pronounced for those in their early 40s and 50s, with annual rises of 2% and 2.6%, respectively.

Between 2021 and 2022, there was a 50% relative increase in diagnoses, jumping from 11.7 to 17.5 cases per 100,000 people. In 2023, approximately 153,000 people were diagnosed with colorectal cancer, and about 52,000 died, including 19,000 cases and 3,750 deaths in people under 50.

Advancing age is the primary risk factor for colorectal cancer, which originates in the inner lining of the colon and can spread aggressively. Early detection offers a high survival rate—about 91%—but this drops to 73% for stage III and 13% for stage IV. A 2016 report found that over three-quarters of younger patients were diagnosed after their cancer had already advanced, a rate higher than that seen in older patients.

Death rates are decreasing among those aged 50 to 64 and 65 and above, but they are rising among adults aged 20 to 40. In people under 55, death rates have increased by about 1% annually since the mid-2000s.

Challenges in Early Detection

Persistent fatigue, abdominal pain, or changes in bowel habits are often dismissed as common issues like stress or irritable bowel syndrome, leading to delays in seeking care. People under 45 are also below the recommended age for routine screening, leaving them vulnerable to undetected early-onset cancers.

Cancer development is a slow, multi-step process that can take decades, beginning with genetic mutations in a single colon cell. Over time, these mutations accumulate, leading to pre-cancerous polyps and eventually malignant tumors. As lifespans increase, so does the likelihood of these genetic errors occurring.

The recent rise in colorectal cancer among younger adults is particularly alarming. When a young person is diagnosed with advanced-stage cancer, it suggests that the biological precursors have developed rapidly, compressing a process that usually takes 20 to 30 years into just 10 or 15.

Ongoing Research and Concerns

The reasons behind this accelerated growth remain unclear, with researchers pointing to modern dietary habits, environmental changes, and shifts in the gut microbiome. In the US, early-onset colon cancer diagnoses in people aged 20 to 34 are expected to rise by 90% between 2010 and 2030, while rates in teens have surged 500% since the early 2000s.

Vaccine therapies are among the most promising approaches for cancer prevention and treatment, aiming to detect and destroy cancer cells. However, the US government recently canceled nearly $500 million in grants supporting mRNA vaccines for infectious diseases, though funding for cancer research remains intact.

Some researchers are concerned that the Trump administration may impose restrictions on mRNA vaccines, potentially impacting oncological research. Dr. Ryan Sullivan, a cancer vaccine researcher at Massachusetts General Hospital, emphasized that the safety of mRNA vaccines is well-established, and any regulatory actions could have broader implications.

As the global fight against cancer continues, the potential of mRNA-based therapies remains a critical area of focus, offering hope for future breakthroughs.